The Pharmaceutical Journal
Vol 276 No 7401 p580
20 May 2006

This article
Reprint   Photocopy

  Acrobat Reader

News summary

New IV antibiotic launched

Some complicated infections in adults can now be treated by a new intravenous antibiotic launched by Wyeth.

Tygacil (tigecycline) can be used for the treatment of complicated skin, soft tissue and intra-abdominal infections. The recommended dose is 100mg initially, followed by 50mg every 12 hours for five to 14 days, administered by intravenous injection over 30–60 minutes.

Tygacil is a glycylcycline antibiotic, which inhibits protein translation in bacteria by binding to ribosomal subunits and blocking entry of amino-acyl transfer RNA molecules into ribosomes. This prevents incorportation of amino acid residues into elongating peptide chains.


Notice-board p588